Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
Year: 2018
Type: article
Source: Gynecologic Oncology
Authors: U.A. Matulonis, K.N. Moore, L.P. Martin, I.B. Vergote, C.M. Castro, L. Gilbert, A. Berkenblit, M.J. Birrer, D.M. O'Malley
Institutions: Dana-Farber Cancer Institute, University of Oklahoma Health Sciences Center, Fox Chase Cancer Center, Universitair Ziekenhuis Leuven, Massachusetts General Hospital, McGill University Health Centre, ImmunoGen (United States), Harvard University, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2811460211